DGAP-News: Medios AG
/ Key word(s): Takeover/Corporate Action
19.03.2020 / 13:05
The issuer is solely responsible for the content of this announcement.
Medios AG acquires Kölsche Blister GmbH and raises debt capital to finance growth and possible future acquisitions
Berlin, 19 March 2020 – Medios AG (“Medios”) today signed a purchase agreement to acquire Kölsche Blister GmbH. This will expand Medios’ business model with the service of patient-specific blistering, the patient-related repackaging of finished pharmaceuticals on individual request. In addition, Medios today signed a contract for a syndicated loan led by Deutsche Bank AG in the amount of EUR 62.5 million. The loan is intended to enable Medios to finance future growth and to make further acquisitions if requested.
Manfred Schneider, CEO of Medios AG: “Thanks to the integration of Kölsche Blister GmbH into the Medios Group, we will in future be able not only to guarantee more safety for patients through patient-specific manufacturing and portioning of high-priced medications, but also to contribute to cost reduction. Moreover, Kölsche Blister GmbH, like Medios, follows the highest international quality standards as a GMP-certified manufacturer. This further strengthens our reputation as a leading competence partner for independent specialised pharmacies.”
Kölsche Blister GmbH supplies pharmacies with blistered finished pharmaceuticals. In the 2019 financial year, the Cologne-based company generated sales of EUR 14.3 million with slightly negative results. The purchase price for the acquisition of the company amounts to EUR 3 million and will be paid half each in the form of Medios shares and cash. The new shares to be issued will be created from authorized capital in a capital increase in kind excluding subscription rights. As a result, the share capital of Medios AG will be increased from EUR 14,564,019 to EUR 14,628,590.
Matthias Gärtner, CFO of Medios AG: “With the acquisition of Kölsche Blister GmbH, we are expanding our business model with an attractive service and cover a further component in the Specialty Pharma supply chain. Thanks to this perfect complement we will see some synergy effects in the medium term. Taking out the loan gives us additional flexibility to further promote organic growth and to continue to benefit from the consolidation of the pharmaceutical market through possible further acquisitions in the future.”
About Medios AG
Medios AG is Germany’s first publicly listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard).
19.03.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||+49 30 232 566 – 800|
|Fax:||+49 30 232 566 – 801|
|Listed:||Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Dusseldorf|
|EQS News ID:||1001543|
|End of News||DGAP News Service|